Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Sun Yat-sen University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07549906CT.gov Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study | — | Not Yet Recruiting | — | — | — |
NCT07412613CT.gov Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer | — | Recruiting | — | — | — |
NCT07156682CT.gov QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer | — | Not Yet Recruiting | — | — | — |
NCT05870800CT.gov Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER | — | Recruiting | — | — | — |
NCT06949111CT.gov Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） | — | Recruiting | — | — | — |
NCT06790212CT.gov Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer | — | Not Yet Recruiting | — | — | — |
NCT06899477CT.gov Pre-Operative Treatment in REseCTable COlon CanceR | — | Not Yet Recruiting | — | — | — |
NCT06686576CT.gov A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer | — | Recruiting | — | — | — |
NCT06665087CT.gov CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC | — | Not Yet Recruiting | — | — | — |
NCT06490536CT.gov The Sagittarius Trial | — | Recruiting | — | — | — |
Show 25 more trialsShow fewer
NCT06594692CT.gov Node-Sparing Short-Course Radiation With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: A Randomized, Prospective, Multicenter Study | — | Not Yet Recruiting | — | — | — |
NCT06609551CT.gov ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study | — | Recruiting | — | — | — |
NCT06368141CT.gov Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer | — | Recruiting | — | — | — |
NCT06242418CT.gov CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial) | — | Recruiting | — | — | — |
NCT06014372CT.gov Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06322147CT.gov Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer | — | Unknown | — | — | — |
NCT05062889CT.gov Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients | — | Suspended | — | — | — |
NCT05833672CT.gov Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers | — | Unknown | — | — | — |
NCT05534087CT.gov Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12) | — | Recruiting | — | — | — |
NCT04108481CT.gov Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT04303429CT.gov Adjuvant Chemotherapy in High Risk Stage II Colon Cancer | — | Unknown | — | — | — |
NCT02882269CT.gov Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer | — | Unknown | — | — | — |
NCT02861300CT.gov CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | — | Completed | — | — | — |
NCT02510118CT.gov Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients | — | Unknown | — | — | — |
NCT01729923CT.gov A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT01233505CT.gov Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT01158274CT.gov RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | — | Completed | — | — | — |
NCT01048580CT.gov Study of Perifosine + Capecitabine for Colon Cancer Patients | — | Completed | — | — | — |
NCT00675012CT.gov NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00398879CT.gov Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients | — | Completed | — | — | — |
NCT00084643CT.gov GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors | — | Completed | — | — | — |
NCT00159445CT.gov Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00127036CT.gov Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) | — | Terminated | — | — | — |
NCT00183833CT.gov Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00026234CT.gov Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colon Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capecitabine (this asset) | Sun Yat-sen University | P3 | B · 60 |
| Floxuridine | City of Hope Medical Center | P2 | BBB |
| Oxaliplatin | Sun Yat-sen University | P3 | BB |
| Fluorouracilum | Akeso | P4 | BB |
| Pertuzumab | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | BB |
| Irinotecan | SCRI Development Innovations, LLC | P3 | BB |
| Palbociclib | Lebanese University | P2 | BB |
| Trastuzumab | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | BB |
| Encorafenib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P3 | BB |
+42 more in the Colon Carcinoma cohort
Other indications for Capecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | BBB · 73 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capecitabine in Colon Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capecitabine-colon-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →